The Israeli Health Ministry recently published a comprehensive set of recommendations that could substantially reshape the landscape of medical cannabis prescribing and use across the country. These proposals, developed by a professional committee led by Dr. Gilad Bodenheimer, address various aspects of treatment, from initial indications and prescriptions to administration, monitoring, and strategies for addiction prevention and discontinuation.
According to the Ministry, while cannabis may offer benefits for some patients, it also carries inherent risks, necessitating stringent medical oversight rather than being considered a consumer product. This move comes a decade after a government decision first regulated cannabis for medical and research purposes, as officials reassess the Israeli model amidst a notable increase in usage.
Addressing Evolving Medical Cannabis Use
Data presented to the committee indicated that Israel has become a leading consumer of medical cannabis globally, with licensed patient numbers rising from 33,000 to approximately 140,000. This surge, particularly since recent conflicts, has led more Israelis to seek support for conditions such as pain, anxiety, and trauma, as reported by The Jerusalem Post.
The committee’s findings highlighted several areas of concern:
- A significant proportion (62%) of patients consume more than 30 grams per month.
- Most licenses (88%) involve high THC concentrations.
- The majority of users (up to 98% of licensed purchases) rely on smoking as the primary administration method.
These observations raised concerns about potential health risks associated with smoking and inconsistent administration, prompting a re-evaluation of current practices.
Proposed Changes to Administration
A central recommendation from the committee is the gradual phasing out of smoking medical cannabis over three years. The committee determined that smoking is not an acceptable medical delivery method due to its inconsistent absorption profile and associated health risks. Under the proposed changes, new patients would typically commence treatment with extracts or precision inhalers. Exceptions for smokable cannabis may be considered in limited clinical scenarios, but only under strict supervision and with defined limits.
Furthermore, the recommendations prioritise low initial amounts and advocate for minimising THC concentrations relative to cannabidiol. Certain flexibilities, however, may be allowed for elderly patients and those with terminal illnesses, acknowledging their specific needs.
Integrating Medical Cannabis into Healthcare Systems
A major structural reform proposed is the transfer of full responsibility for medical cannabis treatment to Israel’s health maintenance organisations (HMOs). This means that diagnosis, approval, monitoring, and dispensing would be managed within the HMO system, aiming to integrate cannabis into patients’ medical records and ensure continuity of care. While hospitals could still recommend treatment, final approval and dispensing would require HMO authorisation. Health funds are expected to have approximately one year to prepare for these implementation changes.
Considerations for Specific Conditions and Patient Safety
The committee expressed particular caution regarding cannabis use for post-traumatic stress disorder (PTSD). While not recommending the removal of this indication, it emphasised that current research does not sufficiently demonstrate long-term benefits and raised concerns about potential functional impairment. For severe cases, such as insomnia or acute distress, cannabis may still be considered, but only in conjunction with established treatments like psychotherapy and under close medical supervision.
Strong emphasis was also placed on addiction prevention. Physicians would be required to assess patients’ risk factors before initiating treatment and avoid prescribing cannabis where significant addiction risk is identified. Warning signs include escalating amounts, frequent doctor changes, insistence on specific treatments, and concurrent use of addictive medications. Monthly prescription renewals would be permitted, but extended treatment beyond six months would necessitate an in-person evaluation and a reassessment of benefits versus risks.
Additional measures include mandatory training for healthcare professionals, stricter reporting requirements concerning driving and firearm eligibility, and expanded investment in clinical research. The committee called for collaborative efforts between the Ministry, HMOs, and research institutions, including studies on safer delivery methods such as inhalers. These proposed medical cannabis guidelines aim to balance patient accessibility with enhanced safety and treatment effectiveness.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Hemp Gazette does not provide medical recommendations, diagnoses, or treatment plans. Always consult a qualified healthcare practitioner before making any decisions regarding your health or any medical condition. Statements concerning the therapeutic uses of hemp, cannabis, or cannabinoid-derived products have not been evaluated by Australia’s Therapeutic Goods Administration (TGA). Medicinal cannabis products in Australia are accessed via prescription pathways under TGA regulation.
